PDS Biotechnology Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PDSB in the last 30 days.
See all $PDSB insider activity →PDS Biotechnology (PDSB) will host a virtual KOL event on Oct 15, 2026, to discuss Phase 2 data for PDS0301 in treating metastatic colorectal cancer with liver metastases. The event features NCI investigator Jonathan M. Hernandez and includes a live Q&A.
PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune
PDS Biotechnology (PDSB) disclosed that Nant Capital, led by Patrick Soon-Shiong, acquired a 19.9% stake in the company. Nant Capital purchased 13,005,334 shares and warrants for $0.2825 per share. The investment includes a milestone closing contingent on PDS0301's Phase 3 trial submission to the FDA, with Nant Capital obligated to invest $10M. Soon-Shiong and James Banaag joined PDS Biotechnology's board.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning PDSB (PDS Biotechnology Corp). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
Recent PDSB coverage spans corporate actions, market movers and financial news.
The announcement may generate modest buying interest ahead of the data release.
Positive Phase 2 data could lift PDSB stock and attract partnership interest.
PDS Biotechnology (PDSB) disclosed that Nant Capital, led by Patrick Soon-Shiong, acquired a 19.9% stake in the company. Nant Capital purchased 13,005,334 shares and warrants for $0.2825 per share. The investment includes a milestone closing contingent on PDS0301's Phase 3 trial submission to the FDA, with Nant Capital obligated to invest $10M. Soon-Shiong and James Banaag joined PDS Biotechnology's board.
Equity raise provides cash for late‑stage development, supporting near‑term upside.
The financing improves balance‑sheet strength and funds late‑stage trials, likely supporting the stock.
AlphAI scores every news story that mentions PDSB with an AI model for sentiment and relevance, and aggregates insider trades from PDS Biotechnology Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
PDS Biotechnology (PDSB) will host a virtual KOL event on Oct 15, 2026, to discuss Phase 2 data for PDS0301 in treating metastatic colorectal cancer with liver metastases. The event features NCI investigator Jonathan M. Hernandez and includes a live Q&A.
1 min readPDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune
2 min readPDS Biotechnology (PDSB) disclosed that Nant Capital, led by Patrick Soon-Shiong, acquired a 19.9% stake in the company. Nant Capital purchased 13,005,334 shares and warrants for $0.2825 per share. The investment includes a milestone closing contingent on PDS0301's Phase 3 trial submission to the FDA, with Nant Capital obligated to invest $10M. Soon-Shiong and James Banaag joined PDS Biotechnology's board.
2 min readPDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.
3 min readPDS Biotechnology (PDSB) retired a $6M debt, paying $4.6M in principal and interest. It raised $11.3M via a PIPE financing led by Nant Capital. Funds will support working capital and clinical trials, including PDS0301's late-stage development. Nant committed additional funding and secured a licensing option for PDS0101. The company added two Nant-affiliated directors to its board.
2 min readPDS Biotechnology (PDSB) repaid a $6M promissory note to Yorkville early on Sep 14, 2026, covering $4.6M in principal and interest. The note, issued Jun 15, 2026, had a 10% annual interest rate and was due Jun 15, 2027. The early redemption reduced debt and interest expenses without penalties, according to the company.
1 min readPDS Biotechnology (PDSB) raised $11.3M in a PIPE deal led by Dr. Patrick Soon-Shiong, who joined the board. The funds will repay debt and advance clinical programs, including PDS0301 for colorectal cancer. Soon-Shiong's NantWorks gained a licensing option for PDS0101.
2 min readPDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Exhibit 99.1 PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks Pr
2 min readBluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.
3 min readPDS Biotechnology (PDSB) shares surged 183% to $0.62 after announcing a $22.55 million PIPE financing led by Nant Capital, with participation from existing investors. Nant will gain board representation if it holds 15% or more of the company's stock.
1 min read
